Assessment and Clinical Implications of Visceral Obesity

Definition and Pathophysiology

The American College of Endocrinology and the American Association of Clinical Endocrinologists define Adiposity‑Based Chronic Disease (ABCD) as a neurohormonal‑driven dysregulation of energy balance that produces abnormal mass, distribution, and function of adipose tissue. 1
The American Heart Association notes that visceral adipose tissue (VAT) accumulation represents the high‑risk phenotype for cardiometabolic complications and is distinct from subcutaneous adipose tissue (SAT). 3

Excess VAT is independently correlated with insulin resistance, atherogenic dyslipidemia, type 2 diabetes, and cardiovascular disease, regardless of total body fat. 3
Android (abdominal) obesity carries a significantly higher risk of cardiometabolic events compared with gynoid (lower‑body) obesity. 3
The American College of Endocrinology/AACE emphasizes that BMI alone does not reflect adipose distribution or health impact; waist circumference and waist‑hip ratio are essential additional measurements. 1, 3

Cushing syndrome manifests with central obesity and characteristic fat redistribution. 1
Hypothyroidism can lead to generalized weight gain and possible myxedema. 1
Polycystic ovary syndrome is associated with an android pattern of fat distribution in women. 3

Measurement of waist circumference and calculation of waist‑hip ratio should be performed to assess visceral adiposity. 3
Patients with visceral obesity should be screened for hypertension, diabetes, and dyslipidemia, the most common complications of this condition. 1, 2
Differentiating visceral from subcutaneous fat distribution is essential for accurate risk stratification. 3
The American College of Endocrinology/AACE recommends routine cardiometabolic risk factor screening in individuals identified with visceral obesity. 1